Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 33

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 33
---
 develop and offer formulations and products within these therapeutic
areas that could afford us with gross and operating margins consistent with our current and historical figures. However, our expectations
and assumptions about market potential and patient needs may prove to be wrong, and we may invest capital and other resources on products,
drug candidates, and formulations that do not generate sufficient revenues for us to recoup our investment.

We may be unable to successfully develop and
commercialize our drug products, candidates or any other assets we may acquire. 

We have acquired assets related
to drug products and drug candidates. We are currently pursuing development and commercialization opportunities with respect to a number
of these products and drug candidates, and we are in the process of assessing certain of our other assets in order to determine whether
to pursue their development or commercialization. In addition, we expect to consider the acquisition of additional intellectual property
rights or other assets in the future. Once we decide to pursue a potential drug candidate, we develop a commercialization strategy for
it, which may include pursuing FDA approval of the drug candidate. We may incorrectly assess the risks and benefits of the commercialization
options or we may not pursue a commercialization strategy that proves to be successful. If we are unable to successfully commercialize
one or more of our drug products and drug candidates, our operating results would be adversely affected. Even if we are able to successfully
sell one or more drug products and drug candidates, we may never recoup our investment in acquiring or developing the drug products and
drug candidates. Our failure to identify and expend our resources and technologies with commercial potential and execute an effective
commercialization strategy for each of our drug products and drug candidates would negatively impact the long-term profitability of our
business.

We may need additional capital in order to
continue operating our business and to operate as a going concern, and such additional funds may not be available when needed, on acceptable
terms, or at all.

We may need significant additional
capital to execute our business plan, execute on future acquisitions and fund our proposed business operations. Additionally, our plans
may change or the estimates of our operating expenses and working capital requirements could be inaccurate, we may pursue acquisitions
of FDA-approved products, drug candidates, pharmacies or other strategic transactions that involve large expenditures, or we may experience
growth more quickly or on a larger scale than we expect, any of which may result in the depletion of capital resources more rapidly than
anticipated and could require us to seek additional financing earlier than we expect to support our operations